Form 4: Relmada Therapeutics Executive Paul Kelly Buys 200,000 Shares in Open Market

Relmada Therapeutics' Chief Operating Officer, Paul Edward Kelly, recently acquired 200,000 shares of common stock in the open market at an average price of $0.4303 per share.

Summary

• On May 16, 2025, Paul Edward Kelly, the Chief Operating Officer of Relmada Therapeutics, Inc. (RLMD), purchased 200,000 shares of the company's common stock.
• The shares were acquired through multiple open market transactions.
• The weighted average purchase price was $0.4303 per share.
• The purchase prices ranged from $0.4071 to $0.4498 per share.
• Following the reported transaction, Kelly directly owns 412,295 shares of Relmada Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. Insider buying is generally viewed favorably, but the impact depends on the size of the purchase relative to the executive's holdings and the company's market capitalization.

Positives

• The purchase of a significant number of shares by a company executive can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive sign, but should be considered in conjunction with other factors.

Stakeholder Impact

• The stock purchase could have a slightly positive impact on shareholder sentiment.

Key Dates

Keywords

Relmada Therapeutics, RLMD, Paul Edward Kelly, Chief Operating Officer, stock purchase, open market, Form 4, insider trading